HLA antibody detection with solid phase assays: Great expectations or expectations too great?

American Journal of Transplantation

Volumn 14, Issue 9, 2014, Pages 1964-1975

  Gebel, H M ^a   Bray, R A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alloantibody; alloantigen; clinical research practice; crossmatch; flow cytometry; histocompatibility; immunobiology

Indexed keywords

ALLOANTIBODY; DNA; HLA ANTIBODY; HLA ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; AUTOANTIBODY;

ANALYTIC METHOD; ANTIBODY DETECTION; ASSAY; EXPECTATION; FLOW CYTOMETRY; HISTOCOMPATIBILITY TEST; HUMAN; ORGAN DONOR; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SEROLOGY; SOLID; SOLID PHASE ASSAY; THEORY; BLOOD; HISTOCOMPATIBILITY; IMMUNOLOGY;

AUTOANTIBODIES; FLOW CYTOMETRY; HLA ANTIGENS; HUMANS; TRANSPLANTATION IMMUNOLOGY;

EID: 84906262423     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12807     Document Type: Review

References (66)

1. Patel R, Terasaki PI., Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735-739.
2. Gebel HM, Bray RA, Nickerson PW., Pretransplant assessment of donor reactive, HLA specific antibodies in renal transplantation: Contraindication vs risk. Am J Transplant 2003; 3: 1488-1500.
3. Kittleson MM, Kobashigawa JA., Antibody-mediated rejection. Curr Opin Organ Transplant 2012; 17: 551-557.
4. Lobo LJ, Aris RM, Schmitz J, Neuringer IP., Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 2013; 32: 70-77.
5. Campbell PM, Salam A, Ryan EA, et al. Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation. Am J Transplant 2007; 7: 1242-1248.
6. Spellman S, Bray R, Rosen-Bronson S, et al. The detection of DSA in recipients of unrelated hematopoietic SCT is predictive of graft failure. Blood 2010; 115: 2704-2708.
7. O'Leary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 13: 954-960.
8. Gebel HM, Liwski RS, Bray RA., Technical aspects of HLA antibody testing. Curr Opin Organ Transplant 2013; 18: 455-462.
9. Saiki RK, Scharf S, Faloona F, et al. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 1985; 230: 1350-1354.
10. Fulton RJ, McDade RL, Smith PL, Kienker LJ, Kettman JR Jr., Advanced multiplexed analysis with the FlowMetrix system. Clin Chem 1997; 43: 1749-1756.
11. Itoh Y, Mizuki N, Shimada T, et al. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 2005; 57: 717-729.
12. Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and Non-HLA antibodies in transplantation. Transplantation 2013; 95: 19-47.
13. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The Emory algorithm. Am J Transplant 2006; 6: 2307-2315.
14. Taylor CJ, Kosmoliaptsis V, Sharples LD, et al. Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation. Transplantation 2010; 89: 185-193.
15. Appel JZ III, Hartwig MG, Cantu E III, Palmer SM, Reinsmoen NL, Davis RD., Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006; 81: 1049-1057.
16. Zangwill S, Ellis T, Stendahl G, Zahn A, Berger S, Tweddell J., Practical application of the virtual crossmatch. Pediatr Transplant 2007; 11: 650-654.
17. Ferrari P, Fidler S, Wright J, et al. Virtual crossmatch approach to maximize matching in paired kidney donation. Am J Transplant 2011; 11: 272-278.
18. Cecka JM, Kucheryavaya AY, Reinsmoen NL, Leffell MS., Calculated PRA: Initial results show benefits for sensitized patients and a reduction in positive crossmatches. Am J Transplant 2011; 11: 719-724.
19. http://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/ policy-7.pdf. Accessed September 23, 2013.
20. Nikaein A, Cherikh W, Nelson K, et al. Organ procurement and transplantation network/united network for organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients. Transplantation 2009; 87: 557-562.
21. Tambur AR, Ramon DS, Kaufman DB, et al. Perception versus reality? Virtual crossmatch-How to overcome some of the technical and logistic limitations. Am J Transplant 2009; 9: 1886-1893.
22. Bachelet T, Couzi L, Guidicelli G, et al. Anti-Cw donor-specific alloantibodies can lead to positive flow cytometry crossmatch and irreversible acute antibody-mediated rejection. Am J Transplant 2011; 11: 1543-1544.
23. DeVos JM, Gaber AO, Knight RJ, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int 2012; 82: 598-604.
24. Thaunat O, Hanf W, Dubois V, et al. Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: Insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. Transplant Immunol 2009; 20: 209-211.
25. Cecka JM., Calculated PRA: The new measure of sensitization for transplant candidates. Am J Transplant 2010; 10: 26-29.
26. Bray RA, Tarsitani C, Gebel HM, Lee JH., Clinical cytometry and progress in HLA antibody detection. Methods Cell Biol 2011; 103: 285-310.
27. Bingaman AW, Murphey CL, Palma-Vargas J, Wright F., A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation. Transplantation 2008; 86: 1864-1868.
28. Murphey CL, Bingaman AW., Histocompatibility considerations for kidney paired donor exchange programs. Curr Opin Organ Transplant 2012; 17: 427-432.
29. Claas FH, van Rood JJ., The hyperimmunized patient: From sensitization toward transplantation. Transpl Int 1988; 1: 53-57.
30. Claas FH, Rahmel A, Doxiadis II., Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88: 447-452.
31. http://srtr.transplant.hrsa.gov/annual-reports/2011/flash/01-kidney/ index.html. Accessed August 20, 2013.
32. http://srtr.transplant.hrsa.gov/annual-reports/2010/flash/01-kidney/ index.html. Accessed March 15, 2013.
33. Gebel H, Kasiske B, Gustafson S, et al. Allocating deceased donor kidneys to high PRA patients: A simulation. Am J Transplant 2013; 13: 178.
34. Tambur AR, Leventhal JR, Zitzner JR, Walsh RC, Friedewald JJ., The DQ barrier: Improving organ allocation equity using HLA-DQ information. Transplantation 2013; 95: 635-640.
35. Ling M, Marfo K, Masiakos P, et al. Pretransplant anti-HLA-Cw and anti-HLA-DP antibodies in sensitized patients. Hum Immunol 2012; 73: 879-883.
36. Otten HG, Verhaar MC, Borst HP, Hené RJ, van Zuilen AD., Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012; 12: 1618-1623.
37. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11: 2132-2143.
38. Amico P, Hirt-Minkowski P, Hönger G, et al. Risk stratification by the virtual crossmatch: A prospective study in 233 renal transplantations. Transpl Int 2011; 24: 560-569.
39. Caro-Oleas JL, González-Escribano MF, Gentil-Govantes MÁ, et al. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation. Transplantation 2012; 94: 338-344.
40. Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21: 1398-1406.
41. Poli F, Benazzi E, Innocente A, et al. Heart transplantation with donor-specific antibodies directed toward denatured HLA-A*02:01: A case report. Hum Immunol 2011; 72: 1045-1048.
42. Jacob EK, De Goey SR, Gandhi MJ., Positive virtual crossmatch with negative flow crossmatch results in two cases. Transpl Immunol 2011; 25: 77-81.
43. Pereira S, Perkins S, Lee JH, et al. Donor-specific antibody against denatured HLA-A1: Clinically nonsignificant ? Hum Immunol 2011; 72: 492-498.
44. Zoet YM, Brand-Schaaf SH, Roelen DL, Mulder A, Claas FH, Doxiadis II., Challenging the golden standard in defining donor-specific antibodies: Does the solid phase assay meet the expectations ? Tissue Antigens 2011; 77: 225-228.
45. Süsal C, Ovens J, Mahmoud K, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: A Collaborative Transplant Study report. Transplantation 2011; 91: 883-887.
46. Zachary A, Reinsmoen NL., Quantifying HLA-specific antibodies in patients undergoing desensitization. Curr Opin Organ Transplant 2011; 16: 410-415.
47. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582-589.
48. Congy-Jolivet N, Drocourt D, Portet S, Tiraby G, Blancher A., Production and characterization of chimeric anti-HLA monoclonal antibodies targeting public epitopes as tools for standardizations of the anti-HLA antibody detection. J Immunol Methods 2013; 390: 41-51.
49. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D., HLA antibody specification using single-antigen beads-A technical solution for the prozone effect. Transplantation 2011; 92: 510-515.
50. Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369: 1215-1226.
51. Reed EF, Rao P, Zhang Z, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant 2013; 13: 1859-1870.
52. Pei R, Lee J, Chen T, Rojo S, Terasaki PI., Flow cytometric detection of HLA antibodies using a spectrum of microbeads. Hum Immunol 1990; 60: 1293-1302.
53. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI., Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43-49.
54. Ellis TM, Schiller JJ, Roza AM, Cronin DC, Shames BD, Johnson CP., Diagnostic accuracy of solid phase HLA antibody assays for prediction of crossmatch strength. Hum Immunol 2012; 73: 706-710.
55. Gombos P, Opelz G, Scherer S, et al. Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant 2013; 13: 2075-2082.
56. http://optn.transplant.hrsa.gov/resources/allocationcalculators.asp? index=78. Accessed July 14, 2014.
57. Sicard A, Amrouche L, Suberbielle C, et al. Outcome of kidney transplantations performed with preformed donor-specific antibodies of unknown etiology. Am J Transplant 2014; 14: 193-201.
58. Otten HG, Verhaar MC, Borst HP, et al. The significance of pretransplant donor-specific antibodies reactive with intact or denatured human leucocyte antigen in kidney transplantation. Clin Exp Immunol 2013; 173: 536-543.
59. El-Awar NR, Terasaki PI, Hajeer A, et al. A novel HLA class I single antigen bead preparation eliminates false positive reactions attributed to natural antibodies in the sera of normal males and pre-transplant patients. Hum Immunol 2010; 71 (Suppl 1): S26.
60. Ellis TM., Interpretation of HLA single antigen bead assays. Transplant Rev 2013; 27: 108-111.
61. Willicombe M, Brookes P, Santos-Nunez E, et al. Outcome of patients with preformed donor-specific antibodies following alemtuzumab induction and tacrolimus monotherapy. Am J Transplant 2011; 11: 470-477.
62. Chen G, Sequeira F, Tyan DB., Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011; 72: 849-858.
63. Tinckam KJ, Heeger PS., Transplantation: Complementing donor-specific antibody testing. Nat Rev Nephrol 2013; 9: 713-714.
64. Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D., HLA antibody specification using single antigen beads-a technical solution for the prozone effect. Transplantation 2011; 92: 510-515.
65. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157-1167.
66. Gebel HM, Bray RA., In search of perfection. Am J Transplant 2013; 13: 1951-1952.